SDZ 224-015

Names

[ Name ]:
SDZ 224-015

Biological Activity

[Description]:

SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM)[1][2].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

Signaling Pathways >> Anti-infection >> SARS-CoV

Signaling Pathways >> Apoptosis >> Caspase

Research Areas >> Inflammation/Immunology

[In Vivo]

SDZ 224-015 (0.3-300 μg/kg) potently reduces carrageenin-induced paw oedema[2]. SDZ 224-015 (0.2-5 mg/kg, p.o.) displays analgesic activity in the Randall-Selitto yeast-inflamed paw pressure test, significant at a dose of 1 mg/kg[2].

[References]

[1]. Martin A Redhead, et al. Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Sci Rep. 2021 Jun 24;11(1):13208.

[2]. P R Elford, et al. Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115(4):601-6.

Chemical & Physical Properties

[ Molecular Formula ]:
C₃₀H₃₅Cl₂N₃O₉

[ Molecular Weight ]:
652.52

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.